The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00498667
Recruitment Status : Withdrawn
First Posted : July 10, 2007
Last Update Posted : May 6, 2015
Information provided by (Responsible Party):
e_dann, Rambam Health Care Campus

Brief Summary:
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Condition or disease
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Detailed Description:
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma
Study Start Date : December 2006
Primary Completion Date : December 2009
Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

all patients with aggressive lymphoma who had a baseline and interim pet/ct study

Primary Outcome Measures :
  1. progression free survival [ Time Frame: 5 years ]

Biospecimen Retention:   None Retained
no biopsies are to be retained

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all patients with agressive non hodgkin lymphoma who had interim pet/ct during therapy

Inclusion Criteria:

  • aggressive non-Hodgkin lymphoma b cells
  • age 18-70
  • bilirubin less then 2
  • creatinine less then 2
  • Pet/CT performed post 2 cycles

Exclusion Criteria:

  • no PET/CT post 2 cycles performed
  • bilirubin >2
  • creatinine more then 2
  • HIV positivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00498667

RAMBAM health care Campus
Haifa, Israel, 31096
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Eldad J Dann, MD RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute

Responsible Party: e_dann, Prof Eldad Dann, Rambam Health Care Campus Identifier: NCT00498667     History of Changes
Other Study ID Numbers: cc-NHL2615_CTIL
First Posted: July 10, 2007    Key Record Dates
Last Update Posted: May 6, 2015
Last Verified: May 2015

Keywords provided by e_dann, Rambam Health Care Campus:
Aggressive non-Hodgkin Lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell